THE START OF THE PROFID EHRA CLINICAL TRIAL
With the initiation of the first clinical study sites in Bad Segeberg and Rothenburg, Germany, and the enrolment of the first patients, the PROFID EHRA trial has finally started. From now on the 30-month recruitment period is underway. The PROFID EHRA trial (NCT05665608) is set to answer the question if routine implantation of an implantable …
PROFID AT ESC 2023
This year, PROFID had a marked presence at the European Society of Cardiology 2022 Congress, the world’s largest cardiovascular congress, during the session “Latest Science in Arrhythmias”. Project coordinator Dr. Nikolaos Dagres of the Leipzig Heart Institute presented the final results of the PROFID analysis.
PROFID EHRA COLLABORATION
We are pleased to announce that a very important step for the clinical trial has been taken. Since the start of the PROFID project in 2020, EHRA highly supports the project and the involved trial as a consortium partner via the ESC. This close cooperation between PROFID and EHRA has now been further strengthened; in …
Interview – THE START OF THE PROFID CLINICAL TRIAL
The PROFID trial aims to reassess the role of routine prophylactic ICD implantation in patients with reduced LVEF ≤ 35% after myocardial infarction under contemporary OMT and is designed to be as close to routine clinical care as possible. The start of the PROFID clinical trial is a huge milestone.
7TH GENERAL ASSEMBLY MEETING
The 7th PROFID General Assembly Meeting was held on 5 July 2023 in Berlin. After a long period of web meetings due to the COVID-19 pandemic, it was the first face-to-face meeting after the project kick-off event in 2020. All work package leaders presented the current status of their work. In addition, the start of …
PROFID AT EHRA 2023
We had the great opportunity to present PROFID to world-leading cardiology experts at the EHRA Congress 2023 in Barcelona.
Gerhard Hindricks gave a presentation about the “Generation of novel randomized evidence for the role of primary prevention ICD under contemporary treatment”, in which he showed once again why the PROFID project is urgently needed for the improvement of patient care.
PROFID featured in “Cardio News”, the cardiology journal of the German Cardiac Society
In a news article released in March 2023, Dr. Nikolaos Dagres and Prof. Gerhard Hindricks, chief investigators and coordinators of the PROFID project, present new strategies in order to reassess the role of routine prophylactic defibrillator implantation for primary prevention of SCD.
Interview – THE PROFID CLINICAL TRIAL
After extensive 2.5 years, the PROFID data analysis has been completed. The results, which were presented at the ESC Congress 2022 in Barcelona, have significant implications for the setup of the randomized trial programme. We are currently finalizing an updated design of the PROFID clinical trial, in order to start the submissions to the Ethics Committees at the beginning of 2023.
CONDUCTING THE PROFID TRIAL
The Clinical Research Institute in Munich, Germany, is a full-service Contract Research Organisation (CRO) specialized in large international, commercial and non-commercial (academic) clinical studies in Europe covering both, drug trials and medical device studies.